Tests génomiques pour le traitement du cancer L’un des plus grands défis dans le traitement du cancer est que chaque cancer se comporte différemment. Nombreuses questions se posent telles que : Va-t-i... Read More
EndoPredict: Now Available in Australia, Offering Personalized Breast Cancer Management We are excited to announce that the EndoPredict test, a leading prognostic tool for early-stage breast cancer, is now available in Australia with NATA accredit... Read More
Genomische Testung Eine der größten Herausforderungen bei der Behandlung von Krebs ist, dass sich jeder Krebs anders verhalten kann. Wird er schnell oder langsam wachsen? Wird ... Read More
Genomic testing for cancer treatment One of the biggest challenges in treating cancer is that each one can behave differently to the next. Will it grow fast, or slow? Will it spread to other organ... Read More
New publication: Real-world study prospectively shows prognostic and predictive accuracy We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification an... Read More
NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer New guidance from the National Institute for Health and Care Excellence (NICE)1 The National Institute for Health and Care Excellence (NICE) in the UK has i... Read More
Phase III validation of EndoPredict® confirms prognostic power Prognostic value of EndoPredict® test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer scre... Read More
Updated ESMO Guidelines 2024 Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinica... Read More